Antiviral agents and HIV prevention: Controversies, conflicts, and consensus

AIDS

Volumn 26, Issue 13, 2012, Pages 1585-1598

  Cohen, Myron S ^a,b   Muessig, Kathryn E ^a   Smith, M Kumi ^b   Powers, Kimberly A ^a,b   Kashuba, Angela D M ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

antiretroviral agents; HIV prevention; preexposure prophylaxis; treatment as prevention

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DAPIVIRINE; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; INDINAVIR PLUS RITONAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TMC 278 LA; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMOPROPHYLAXIS; CONDOM; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDEMIC; FEMALE; FEMALE GENITAL SYSTEM; HETEROSEXUALITY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; MALE GENITAL SYSTEM; MALE HOMOSEXUAL; MATHEMATICAL MODEL; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST EXPOSURE PROPHYLAXIS; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; REVIEW; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VAGINA RING; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CONSENSUS; DISEASE PROGRESSION; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MEDICATION ADHERENCE; POST-EXPOSURE PROPHYLAXIS;

EID: 84865489576     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283543e83     Document Type: Review

References (144)

1. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601. (Pubitemid 351650540)
2. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010; 50:S85-S95.
3. Mayer KH, Venkatesh KK. Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health 2010; 100:1867-1876.
4. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre and postexposure prophylaxis. AIDS 2007; 21:1899-1907. (Pubitemid 47329766)
5. Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther 2010; 88:598-609.
6. Pereira AS, Kashuba AD, Fiscus SA, Hall JE, Tidwell RR, Troiani L, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999; 180:2039-2043.
7. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43:1817-1826. (Pubitemid 29395171)
8. Ghosn J, Chaix ML, Peytavin G, Rey E, Bresson JL, Goujard C, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004; 18:1958-1961. (Pubitemid 39313214)
9. Barroso PF, Schechter M, Gupta P, Bressan C, Bomfim A, Harrison LH. Adherence to antiretroviral therapy and persistence of HIV RNA in semen. J Acquir Immune Defic Syndr 2003; 32:435-440. (Pubitemid 36363159)
10. Bujan L, Daudin M, Matsuda T, Righi L, Thauvin L, Berges L, et al. Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS 2004; 18:757-766. (Pubitemid 38535003)
11. Eron JJ, Smeaton LM, Fiscus SA, Gulick RM, Currier JS, Lennox JL, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850). J Infect Dis 2000; 181:1622-1628. (Pubitemid 30387753)
12. Leruez-Ville M, Dulioust E, Costabliola D, Salmon D, Tachet A, Finkielsztejn L, et al. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). AIDS 2002; 16:486-488. (Pubitemid 34165383)
13. Sheth PM, Kovacs C, Kemal KS, Jones RB, Raboud JM, Pilon R, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009; 23:2050-2054.
14. Krieger JN, Coombs RW, Collier AC, Ho DD, Ross SO, Zeh JE, et al. Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. J Urol 1995; 154:1035-1040.
15. Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489-2497.
16. Neely MN, Benning L, Xu J, Strickler HD, Greenblatt RM, Minkoff H, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38-42. (Pubitemid 46052218)
17. Launay O, Tod M, Tschope I, Si-Mohamed A, Belarbi L, Charpentier C, et al. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther 2011; 16:843-852.
18. Marcelin AG, Tubiana R, Lambert-Niclot S, Lefebvre G, Dominguez S, Bonmarchand M, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS 2008; 22:1677-1679.
19. Mayer KH, Boswell S, Goldstein R, Lo W, Xu C, Tucker L, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999; 28:1252-1259. (Pubitemid 29272799)
20. Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12:F181-F189. (Pubitemid 28479268)
21. Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, et al. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J Antimicrob Chemother 2008; 61:1344-1347. (Pubitemid 351753606)
22. Cohen J. HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 2011; 334:1614.
23. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
24. Taylor S, Sadiq ST, Weller I, Kaye S, Workman J, Cane PA, et al. Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections. Antivir Ther 2003; 8:479-483. (Pubitemid 37351567)
25. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20:2305-2313. (Pubitemid 44789532)
26. Attia S, Egger M, Mü ller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
27. Guthrie BL, de Bruyn G, Farquhar C. HIV-1-discordant couples in sub-Saharan Africa: explanations and implications for high rates of discordancy. Curr HIV Res 2007; 5:416-429. (Pubitemid 47040483)
28. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101. (Pubitemid 41233212)
29. Del Romero J, Castilla J, Hernando V, Rodriguez C, Garcia S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ 2010; 340:c2205.
30. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
31. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92. (Pubitemid 41818118)
32. Hernando V, del Romero J, Garcia S, Rodriguez C, del Amo J, Castilla J. Reducing sexual risk behavior among steady heterosexual serodiscordant couples in a testing and counseling program. Sex Transm Dis 2009; 36:621-628.
33. Melo MG, Santos BR, De Cassia Lira R, Varella IS, Turella ML, Rocha TM, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis 2008; 35:912-915.
34. Musicco M, Lazzarin A, Nicolosi A, Gasparini M, Costigliola P, Arici C, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994; 154:1971-1976. (Pubitemid 24276382)
35. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25:473-477.
36. Sullivan P, Kayitenkore K, Chomba E, Karita E, Mwananyanda L, Vwalika C. Reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT): Misclassification of ARVT status as a methodological issue. AIDS Res Hum Retroviruses 2010; 26:A1-A184.
37. Wang L, Ge Z, Luo J, Shan D, Gao X, Ding GW, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr 2010; 55:232-238.
38. Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001; 15:621-627. (Pubitemid 32281358)
39. Vernazza PL, Hirschelb B. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antire ́troviral efficace ne transmettent pas le VIH par voie sexuelle. [HIV-infected patients under HAART without any other sexually transmitted infection do not transmit HIV by sexual intercourse.] Bull Med Suisse 2008; 89:165-169.
40. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR, Jeannin A, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV Cohort Study. Clin Infect Dis 2010; 51:1314-1322.
41. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy.NEngl J Med 2011; 365:493-505.
42. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS 2012; 7:99-105.
43. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
44. Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antiviral Ther 2008; 13:177-187. (Pubitemid 351535369)
45. Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21:1717-1721. (Pubitemid 47237558)
46. PEPFAR Scientific Advisory Board. PEPFAR Scientific Advisory Board Recommendations for the Office of the US Global AIDS Coordinator: implications of HPTN 052 for PEPFAR's Treatment Programs. 2011. http://www.pepfar.gov/ documents/organization/177126.pdf. [Accessed 13 March 2012]
47. World Health Organization. WHO and U.S. NIH Working Group Meeting on treatment for HIV prevention among MSM: what additional evidence is required? 26-27 October 2011; Geneva, Switzerland. http://www.who.int/hiv/pub/msm-meeting- report.pdf. [Accessed 13 March 2012]
48. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010; 84:6241-6247.
49. Copenhagen HIV Program Denmark and Royal Free School and UC Medical School. Partners of people on ART: a New Evaluation of the Risks (PARTNER study). http://www.partner study.eu/. [Accessed 13 March 2012]
50. Kirby Institute for Infection and Immunity in Society. 'Opposites Attract: The study of relationships between HIV positive and negative gay men'. Study website: www.oppositesattract. net.au. [Accessed 23 April 2012]
51. Castel A, Befus M, West-Ojo T, Giffin A, Hader S, Kamanu-Elias N. Use of community viral load as population-based biomarker of HIV-Washington, DC, 2004-2008. In: Proceedings of the 18th Annual Conference on Retroviruses and Opportunistic Infections; 2011; Boston, MA.
52. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.
53. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539.
54. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338:b1649.
55. Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
56. Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-394. (Pubitemid 34184826)
57. Law MG, Woolley I, Templeton DJ, Roth N, Chuah J, Mulhall B, et al. Trends in detectable viral load by calendar year in the Australian HIV observational database. J Int AIDS Soc 2011; 14:10.
58. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88. (Pubitemid 38402321)
59. Stoltz JA, Wood E, Small W, Li K, Tyndall M, Montaner J, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf) 2007; 29:35-39.
60. Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ 2006; 175:1399-1404. (Pubitemid 44876560)
61. Wood E, Montaner J, Yip B, Tyndall M, Schechter M, O'Shaughnessy MV, Hogg RS. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 Infected injection drug users. CMAJ 2003; 169:656-661. (Pubitemid 37266973)
62. Dukers NH, Spaargaren J, Geskus RB, Beijnen J, Coutinho RA, Fennema HS. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS 2002; 16:F19-F24. (Pubitemid 34722061)
63. Wand H, Yan P, Wilson D, McDonald A, Middleton M, Kaldor J, et al. Increasing HIV transmission through male homosexual and heterosexual contact in Australia: results from an extended back-projection approach. HIV Med 2010; 11:395-403.
64. Murray JM, Prestage G, Grierson J, Middleton M, McDonald A. Increasing HIV diagnoses in Australia among men who have sex with men correlated with the growing number not taking antiretroviral therapy. Sexual Health 2011; 8:304-310.
65. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006-
66. Le Vu S, Le Strat Y, Barin F, Pillonel J, Cazein F, Bousquet V, et al. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 2010; 10:682-687.
67. British Columbia Center for Disease Control. HIV and sexually transmitted infections. 2010. http://www.bccdc.ca/util/about/annreport/default. htm#heading1. [Accessed 13 March 2012]
68. UNAIDS. 2011-2015 strategy: getting to zero. Joint United Nations Programme on HIV/AIDS. http://www.unodc.org/documents/eastasiaandpacific/ Publications/2011/JC2034-UNAIDS-Strategy-en.pdf. [Accessed 13 March 2012]
69. Tanser F, Barnighausen T, Grapsa E, Newell ML. Effect of ART coverage on rate of new HIV infections in a hyper endemic, rural population: South Africa. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 2012; Seattle, WA.
70. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al. Antiretrovirals therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 2011; 9:446-469.
71. US National Institute of Allergy and Infectious Diseases, US National Institutes of Health. HPTN 065 TLC-Plus: a study to evaluate the feasibility of an enhanced test, link to care, plus treat approach for HIV prevention in the United States. 2010. http://www.hptn.org/research-studies/hptn065.asp. [Accessed 13 March 2012]
72. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the 'test-andtreat' approach to reduce HIV transmission. PLoS One 2010; 5:e10148.
73. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
74. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010; 51:725-731.
75. US Centers for Disease Control. Only one quarter of Americans with HIV have virus under control. 2011. http://www.cdc. gov/nchhstp/newsroom/ WAD2011PressRelease.html. [Accessed 13 March 2012]
76. Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:277-282.
77. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med 2011; 364:1943-1954.
78. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959. (Pubitemid 46452099)
79. Frange P, Meyer L, Deveau C, Tran L, Goujard C, Ghosn J, et al. Recent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequency. PLoS One 2012; 7:e31695.
80. Cohen M, Dye C, Fraser C, Miller W, Powers K, Williams B. Does transmission during early HIV infection compromise treatment as prevention? PLoS Med (in press).
81. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
82. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
83. Thigpen M, Kebaabetswe P, Smith D, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. In: Proceedings of the 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; 17-20 July 2011; Rome. WELBC01 oral abstract.
84. Baeten J, Celum C. Antiretroviral preexposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP study. In: Proceedings of the 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; 17-20 July 2011; Rome.
85. FEMem-PrEP Project. FHI360. http://www.fhi.org/en/Research/Projects/FEM- PrEP.htm. [Accessed 13 March 2012]
86. Microbicide Trials Network. VOICE (MTN-003) Study. http://www. mtnstopshiv.org/news/studies/mtn003. [Accessed 13 March 2012]
87. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.
88. Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2:14ra14.
89. Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012. [Epub ahead of print]
90. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. The FEM-PrEP Trial of emtricitabine/tenofovir disoproxil fumarate (Truvada) among African women. In: Proceedings of the 19th Conference on Retrovirusus and Opportunistic Infections; 2012; Seattle, WA.
91. Baeten J, Donnell D, Ndase P, Mugo N, Mujugira A, Celum C, et al. ARV PrEP for HIV-1 Prevention among Heterosexual Men and Women. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 2012; Seattle, WA.
92. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis 2011; 203:1484-1490.
93. Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Preexposure prophylaxis for HIV prevention: how to predict success. Lancet 2011. [Epub ahead of print]
94. HIV Prevention Trials Network. HPTN 067: the ADAPT study. http://www.hptn.org/research-studies/hptn067.asp. [Accessed 13 March 2012]
95. iPrEx OLE. What is iPrEx OLE? http://iprexole.com/1pages/abou tus/aboutus-whatisiprexole.php. [Accessed 13 March 2012]
96. The French National Agency for Research on AIDS and viral hepatitis. IPERGAY un essai ANRS. http://www.ipergay.fr/. [Accessed 13 March 2012]
97. HIV Prevention Trials Network. HPTN 069: next PrEP study. http://www.hptn.org/research-studies/hptn069.asp. [Accessed 13 March 2012]
98. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res 2010; 88 (Suppl 1):S30-S39.
99. International Partnership for Microbicides. Dapivirine (TMC120). http://www.ipmglobal.org/our-work/ipm-productpipeline/dapivirine-tmc120. [Accessed 13 March 2012]
100. Nel A, Habibi S, Smythe S, Nuttall J, Lloyd P. Pharmacokinetics and safety assessment of monthly anti-HIV DPV vaginal microbicide rings with multiple dosing. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, MA; paper 1001.
101. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25:483-488.
102. van 't Klooster G, Hoeben E, Borghys H, Looszova A, Bouche MP, van Velsen F, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54:2042-2050.
103. Jackson A, Else L, Tjia J, Seymour N, Stafford M, Back D, et al. Rilpavirine-LA formulation: pharmacokinetics in plasma, genital tract in HIV-negative females and rectum in males. In: Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections; 2012; Seattle.
104. Marcus D, McKay B. Fight over use of HIV drugs. The Wall Street Journal 7 March 2012.
105. Hurt CB, Eron JJ, Cohen MS. Preexposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011; 53:1265-1270.
106. Grant R. Preexposure chemoprophylaxis for HIV prevention (author reply). N Engl J Med 2011; 364:1374-1375.
107. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
108. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008; 49:298-308.
109. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27.
110. Grohskopf L, Pathak S. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 preexposure prophylaxis (PrEP) among U. S. men who have sex with men (MSM). In: Proceedings of the XVIII International AIDS Conference; 2010; Vienna, Austria.
111. Mulligan K, Glidden DV, Gonzales P. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the Global iPrEx Study. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston.
112. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006; 332:605-607. (Pubitemid 44365764)
113. Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007; 4:165-172.
114. Stolte IG, Dukers NH, Geskus RB, Coutinho RA, de Wit JB. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 2004; 18:303-309. (Pubitemid 38253454)
115. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292:224-236. (Pubitemid 38918000)
116. Celum CL. HIV preexposure prophylaxis: new data and potential use. Top Antivir Med 2011; 19:181-185.
117. Blower SM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654. (Pubitemid 30070912)
118. Gray RH, Li X, Wawer MJ, Gange SJ, Serwadda D, Sewankambo NK, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 2003; 17:1941-1951. (Pubitemid 37070280)
119. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006; 3:e124.
120. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
121. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Fraser C. 27 years of the HIV epidemic amongst men having sex with men in the Netherlands: an in depth mathematical model-based analysis. Epidemics 2010; 2:66-79.
122. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729-735.
123. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 2010; 153:778-789.
124. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327:697-701.
125. Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392-400.
126. Baggaley RF, Ferguson NM, Garnett GP. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2005; 2:9.
127. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19:1-14. (Pubitemid 40111013)
128. Cambiano V, Phillips AN. Modelling the impact of treatment with individual antiretrovirals. Curr Opin HIV AIDS 2011; 6:124-130.
129. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis 2011; 52:1046-1049.
130. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Prins M, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008; 22:1071-1077. (Pubitemid 351769746)
131. Xiridou M, Geskus R, de Wit J, Coutinho R. The contribution of steady and casual partnerships to the incidence of HIV infection among homosexual men in Amsterdam. AIDS 2003; 17:1029-1038. (Pubitemid 36549715)
132. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294. (Pubitemid 32592362)
133. Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, Kamanga G, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378:256-268.
134. Bendavid E, Brandeau ML, Wood R, Owens DK.Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med 2010; 170:1347-1354.
135. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123.
136. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B. Evaluating the cost-effectiveness of preexposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 2010; 5:e13646.
137. El-Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS 2011; 25:2295-2299.
138. Shelton JD. HIV/AIDS. ARVs as HIV prevention: a tough road to wide impact. Science 2011; 334:1645-1646.
139. McNeil DG. Clinton aims for 'AIDS-free generation'. The New York Times 8 November 2011. http://www.nytimes.com/2011/11/09/health/policy/hillary-rodham- clinton-aimsfor-aids-free-generation.html. [Accessed 13 March 2012]
140. Office of the Press Secretary, The White House. FACT SHEET: the beginning of the end of AIDS. 2011. http://www.white house. gov/the-press-office/2011/12/ 01/fact-sheet-beginningend-aids. [Accessed 13 March 2012]
141. World Health Organization. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples: Recommendations for a public health approach. 2012. http://www.who.int/hiv/pub/guidelines/9789241501972/en/index.html. [Accessed 24 April 2012]
142. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008; 372:669-684.
143. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralizationresistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.
144. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.